Meeting
2015 ASCO Annual Meeting
A pilot study of tremelimumab – a monoclonal antibody against CTLA-4 – in combination with either trans catheter arterial chemoembolization (TACE) or radiofrequency ablation (RFA) in patients with hepatocellular carcinoma (HCC).
Authors
Austin G. Duffy
National Cancer Institute at the National Institutes of Health, Bethesda, MD
Austin G. Duffy , Oxana V. Makarova-Rusher , Sid P Kerkar , David E Kleiner , Suzanne Fioravanti , Melissa Walker , Stephanie Carey , William Douglas Figg , Seth M. Steinberg , Victoria Anderson , Nadine Abi-Jaoudeh , Elliot Levi , Bradford J. Wood , Tim F. Greten
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer
Clinical Trial Registration Number
NCT01853618
Citation
J Clin Oncol 33, 2015 (suppl; abstr 4081)
DOI
10.1200/jco.2015.33.15_suppl.4081
Abstract #
4081
Poster Bd #
191
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Tremelimumab: A monoclonal antibody against CTLA-4—in combination with subtotal ablation (trans catheter arterial chemoembolization (TACE), radiofrequency ablation (RFA) or cryoablation) in patients with hepatocellular carcinoma (HCC) and biliary tract carcinoma (BTC).
First Author: Austin G. Duffy
Poster
2016 Gastrointestinal Cancers Symposium
![Tremelimumab, a monoclonal antibody against CTLA-4, in combination with subtotal ablation (trans-catheter arterial chemoembolization [TACE], radiofrequency ablation [RFA] or cryoablation) in patients with hepatocellular carcinoma (HCC) and biliary tract carcinoma (BTC).](https://d201v5jt9ylckg.cloudfront.net/173/11384/120467/120467_poster_pv.jpg)
Tremelimumab, a monoclonal antibody against CTLA-4, in combination with subtotal ablation (trans-catheter arterial chemoembolization [TACE], radiofrequency ablation [RFA] or cryoablation) in patients with hepatocellular carcinoma (HCC) and biliary tract carcinoma (BTC).
First Author: Austin G. Duffy
Poster
2021 Gastrointestinal Cancers Symposium
Trial-in-progress: A pilot study of combined immune checkpoint inhibition in combination with ablative therapies in subjects with hepatocellular carcinoma (HCC).
First Author: Hailey Kathryn Carroll
Poster
2017 ASCO-SITC Clinical Immuno-Oncology Symposium
Tremelimumab: A monoclonal antibody against CTLA-4—In combination with radiofrequency ablation (RFA) in patients with biliary tract carcinoma (BTC).
First Author: Austin G. Duffy